Picture of Eris Lifesciences logo

ERIS — Eris Lifesciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareBalancedMid CapFalling Star

India's Eris Lifesciences falls on Q3 profit drop

** Shares of Eris Lifesciences  ERIS.NS  shed 4.3% to
1,196.45 rupees
    ** Drugmaker reports ~19% Y/Y drop in Q3 consol net profit,
profit margin contracts to 11.9% from 20.9% year ago  
    ** Even though revenue grew ~50% Y/Y, it was offset due to
expenses tied to change in ERIS's business mix due to its
acquisition of Biocon's  BION.NS  branded formulations business,
ERIS says
    ** ERIS's total expenses jump ~64% Y/Y
    ** Avg rating of eight analysts on ERIS at "Buy"; median PT
is 1,505 rupees - LSEG data
    ** Stock gained ~51% in 2024


 (Reporting by Kashish Tandon in Bengaluru)
 ((Kashish.tandon@thomsonreuters.com))

Recent news on Eris Lifesciences

See all news